Logo image of CTNM

CONTINEUM THERAPEUTICS INC-A (CTNM) Stock Fundamental Analysis

NASDAQ:CTNM - Nasdaq - US21217B1008 - Common Stock - Currency: USD

4.1  +0.13 (+3.27%)

Fundamental Rating

3

Overall CTNM gets a fundamental rating of 3 out of 10. We evaluated CTNM against 198 industry peers in the Pharmaceuticals industry. While CTNM has a great health rating, there are worries on its profitability. CTNM has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CTNM had negative earnings in the past year.
CTNM had a negative operating cash flow in the past year.
CTNM Yearly Net Income VS EBIT VS OCF VS FCFCTNM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

CTNM has a better Return On Assets (-19.85%) than 61.11% of its industry peers.
CTNM has a Return On Equity of -21.34%. This is in the better half of the industry: CTNM outperforms 70.20% of its industry peers.
Industry RankSector Rank
ROA -19.85%
ROE -21.34%
ROIC N/A
ROA(3y)-16.78%
ROA(5y)N/A
ROE(3y)-21.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CTNM Yearly ROA, ROE, ROICCTNM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CTNM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CTNM Yearly Profit, Operating, Gross MarginsCTNM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 10 20 30 40

More info and screens

8

2. Health

2.1 Basic Checks

CTNM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CTNM has more shares outstanding
CTNM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CTNM Yearly Shares OutstandingCTNM Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M 25M
CTNM Yearly Total Debt VS Total AssetsCTNM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

CTNM has an Altman-Z score of 3.72. This indicates that CTNM is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of CTNM (3.72) is better than 78.79% of its industry peers.
CTNM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.72
ROIC/WACCN/A
WACC9.65%
CTNM Yearly LT Debt VS Equity VS FCFCTNM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

CTNM has a Current Ratio of 20.69. This indicates that CTNM is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CTNM (20.69) is better than 93.94% of its industry peers.
CTNM has a Quick Ratio of 20.69. This indicates that CTNM is financially healthy and has no problem in meeting its short term obligations.
CTNM has a Quick ratio of 20.69. This is amongst the best in the industry. CTNM outperforms 93.94% of its industry peers.
Industry RankSector Rank
Current Ratio 20.69
Quick Ratio 20.69
CTNM Yearly Current Assets VS Current LiabilitesCTNM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

CTNM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -341.52%.
Looking at the last year, CTNM shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)-341.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-82.21%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CTNM is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.05% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y53.02%
EPS Next 2Y18.09%
EPS Next 3Y12.05%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CTNM Yearly Revenue VS EstimatesCTNM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2025 10M 20M 30M 40M
CTNM Yearly EPS VS EstimatesCTNM Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CTNM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CTNM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CTNM Price Earnings VS Forward Price EarningsCTNM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CTNM Per share dataCTNM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

CTNM's earnings are expected to grow with 12.05% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.09%
EPS Next 3Y12.05%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CTNM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CONTINEUM THERAPEUTICS INC-A

NASDAQ:CTNM (5/2/2025, 8:00:01 PM)

4.1

+0.13 (+3.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-06 2025-03-06/amc
Earnings (Next)05-15 2025-05-15
Inst Owners75.4%
Inst Owner Change0%
Ins Owners6.19%
Ins Owner Change-1.27%
Market Cap106.07M
Analysts85.45
Price Target25.3 (517.07%)
Short Float %4.21%
Short Ratio10.67
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.96%
Min EPS beat(2)-28.28%
Max EPS beat(2)4.35%
EPS beat(4)1
Avg EPS beat(4)-172.64%
Min EPS beat(4)-656.61%
Max EPS beat(4)4.35%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-15.21%
PT rev (3m)-15.21%
EPS NQ rev (1m)-3.35%
EPS NQ rev (3m)-20.21%
EPS NY rev (1m)-1.27%
EPS NY rev (3m)-24.95%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-16.67%
Revenue NY rev (3m)-16.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.54
P/tB 0.54
EV/EBITDA N/A
EPS(TTM)-4.9
EYN/A
EPS(NY)-2.3
Fwd EYN/A
FCF(TTM)-1.29
FCFYN/A
OCF(TTM)-1.27
OCFYN/A
SpS0
BVpS7.66
TBVpS7.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.85%
ROE -21.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-16.78%
ROA(5y)N/A
ROE(3y)-21.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 199.23%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 20.69
Quick Ratio 20.69
Altman-Z 3.72
F-Score2
WACC9.65%
ROIC/WACCN/A
Cap/Depr(3y)149.13%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-341.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-82.21%
EPS Next Y53.02%
EPS Next 2Y18.09%
EPS Next 3Y12.05%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-416.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-50.02%
EBIT Next 3Y-45.74%
EBIT Next 5YN/A
FCF growth 1Y-276.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-269.75%
OCF growth 3YN/A
OCF growth 5YN/A